

Hitting the Bullseye With Anti-BCMA Treatment – Clinical Brief #2

References

Tweet 3

Anderson LD Jr, Shah N, Jagannath S, et al. OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa. *Clin Lymphoma Myeloma Leuk*. 2021;21(2):S17-S18. doi:10.1016/s2152-2650(21)02101-7

Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. *Lancet*. 2021;398(10297):314-324. doi:10.1016/S0140-6736(21)00933-8

Usmani SZ, Martin TG, Berdeja JG, et al. Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI. *Journal of Clinical Oncology*. 2022;40(16 suppl):8028-8028. doi:10.1200/JCO.2022.40.16_suppl.8028

Tweet 5

BLENREP (belantamab mafodotin-blmf) [prescribing information]. GlaxoSmithKline. Approved 2020. Revised February 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761158s006lbl.pdf

CARVYKTI™ (ciltacabtagene autoleucel) [prescribing information]. Janssen Biotech, Inc. Approved 2022. Revised February 2022. <https://www.fda.gov/media/156560/download>

ABECMA® (idecabtagene vicleucel) [prescribing information]. Bristol-Myers Squibb. Approved 2021. Revised March 2021. <https://www.fda.gov/media/147055/download>

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Multiple Myeloma (v5.2022). Updated March 9, 2022. Accessed June 2, 2022. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf

Tweet 9

Cohen AD, Parekh S, Santomaso BD, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. *Blood Cancer J*. 2022;12(2):32. doi:10.1038/s41408-022-00629-1

Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood*. 2014;12(32). doi:10.1182/blood-2014-05-552729

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Management of Immunotherapy-Related Toxicities (v1.2022). Updated February 28, 2022. Accessed July 12, 2022. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf

Glossary

ADC, antibody-drug conjugate
AE, adverse event
AST, aspartate aminotransferase
BCMA, B cell maturation antigen
CAR, chimeric antigen receptor
Cilta-cel, ciltacabtagene autoleucel
CRS, cytokine release syndrome
Ide-cel, idecabtagene vicleucel
IMiD, immunomodulatory drug
LOT, line of therapy
mAb, monoclonal antibody
mDOR, median duration of response
MM, multiple myeloma
mOS, median overall survival
mPFS, median progression-free survival
MRD, minimal residual disease
NE, not estimable
ORR, overall response rate
OS, overall survival
PFS, progression-free survival
PI, proteasome inhibitor
RRMM, relapsed/refractory multiple myeloma
w/, with